PULM News and Press, Pulmatrix Inc. From 01/08/24

Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives PR Newswire Cipla to take sole responsibility for development of PUR1900, refocu...

2023-11-09 09:24:01 ET More on Pulmatrix Seeking Alpha’s Quant Rating on Pulmatrix Historical earnings data for Pulmatrix Financial information for Pulmatrix For further details see: Pulmatrix GAAP EPS of -$1.03, revenue of $1.75M

Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update PR Newswire Patient enrollment for the Phase 2b study of PUR1900 is ongoing with four additional sites added during Q3, totaling seventeen active sites to date in four countries; topline...

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...

Pulmatrix Inc. (PULM) is expected to report $-1.05 for Q3 2023

Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine PR Newswire Pulmatrix received a study may proceed letter for a Phase 2 Study to Evaluate PUR3100, an orally inhaled dry powder formulation of dihydroergotamine ("DHE") in the treatment o...

Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole PR Newswire Results demonstrate a low likelihood of clinically meaningful drug-drug interactions when PUR1900 is adm...

2023-08-10 10:32:36 ET Pulmatrix press release ( NASDAQ: PULM ): Q2 GAAP EPS of -$1.04. Revenue of $1.84M (+38.3% Y/Y). For further details see: Pulmatrix GAAP EPS of -$1.04, revenue of $1.84M

Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update PR Newswire Subject enrollment for the Phase 2b study of PUR1900 is ongoing with five additional sites added during Q2, totaling thirteen active sites to date in four countries, and top...

Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine PR Newswire LEXINGTON, Mass. , July 11, 2023 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ: P...